Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radio-Immuno-Modulation (RIM) in Advanced Lung Cancer
NCT02579005Phase 1Suspended
- Start
- Apr 2018
- Primary completion
- Oct 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of allogeneic human umbilical cord blood in Lung Cancer (LC) (2 arms). Primary endpoint: Incidence of treatment-related adverse events at 6 months. Started Apr 2018; status: suspended.
02
Drugs
allogeneic human umbilical cord blood
03
Conditions
Lung Cancer (LC)
Beyond the preview
Go deeper on NCT02579005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02579005.